MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the publication of a research paper in the peer-reviewed journal Melanoma Research validating the geneType for Melanoma risk assessment test in one of the most commonly diagnosed cancers in the Western world, 3rd in Australia and 5th in the United States.
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.
